Salivary duct carcinoma of the parotid gland: A case report and review of the literature

Xie, Shuhua; Yang, Hongyu; Bredell, Marius; Shen, Shiyue; Yang, Huijun; Jin, Long; Zhang, Shanshan

doi:10.3892/ol.2014.2655

Cited by 8 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Salivary ductal carcinoma (SDC) of parotid gland is a rare and aggressive entity; accounting for 1–3 % of all malignant salivary gland tumors, 0.2 % of epithelial salivary gland neoplasms, 0.5 % of salivary gland carcinomas, and 1.1 % of parotid gland carcinomas [ 1 , 2 ]. SDC of parotid gland has been classified as high grade tumors along with high-grade mucoepidermoid carcinoma and carcinoma ex pleomorphic adenoma in the updated World Health Organisation (WHO) classification of salivary gland tumors [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland

Al‐Qahtani

Tunio

Bayoumi

et al. 2016

Journal of Otolaryngology - Head & Neck Surgery

View full text Add to dashboard Cite

BackgroundSalivary ductal carcinoma (SDC) of parotid gland is a rare and aggressive entity; accounting for 1–3 % of all malignant salivary gland tumors, 0.2 % of epithelial salivary gland neoplasms, 0.5 % of salivary gland carcinomas, and 1.1 % of parotid gland carcinomas. Here in we aimed to evaluate the clinico-pathological features and treatment outcomes of parotid gland SDC in Saudi population.MethodsAmong 38 patients with parotid malignancies, who were treated in two major tertiary care referral cancer centers between December 2007 and December 2014, seven cases (18.4 %) were found to have SDC, which were investigated for clinicopathological features, locoregional recurrences (LRRs), distant metastasis (DM) and survival rates.ResultsMean age of cohort was 62.3 years (range: 41–83) and female predominant (71.4 %). All patients underwent total parotidectomy and ipsilateral neck dissection. Mean tumor size was 3.4 cm (range: 2.1–5.3); perineural invasion (85.8 %); lymph node involvement (42.9 %); and HER-2 neu overexpression (28.6 %). Postoperative radiation therapy (PORT) was given to six patients (dose: 50–66 Gy). Median follow-up was 20.2 months (range: 11–48). LRRs were seen in five (71.4 %) patients (base of skull, 3 patients; cervical nodes, one patient; parotid bed, one patient). LRRs were salvaged with resection (two patients) and re-irradiation (one patient with base of skull). DM in lungs was seen in three patients (42.8 %); one treated with carboplatin/paclitaxel based chemotherapy. The 4-year disease free and overall survival rates were 16.7 % and 40 % respectively.ConclusionSDC of parotid gland is a rare and aggressive entity, and most of LRRs were seen in the base of skull, which warrants inclusion of base of skull in clinical target volume in PORT planning. Role of anti HER-2 targeted therapy in SDC with HER-2 neu overexpression needs further investigations.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland

Al‐Qahtani

Tunio

Bayoumi

et al. 2016

Journal of Otolaryngology - Head & Neck Surgery

View full text Add to dashboard Cite

show abstract

“…Recent studies of novel treatment strategies for SDC investigated the systemic use of molecularly targeted therapies (14)(15)(16)(35)(36)(37). Trastuzumab, which targets HER2, effectively prevents the recurrence of metastatic HER2-positive breast cancer.…”

Section: Sdc Was First Described In 1968 Bymentioning

confidence: 99%

“…This type of cancer resembles intraductal and infiltrating mammary duct carcinomas with a variety of histoarchitectural and cytological patterns. Approximately 61-100% of the cases are reported to be human epidermal growth factor receptor 2 (HER2)-positive (13,14), and a correlation has been identified between HER2 expression and prognosis (13)(14)(15)(16). Additionally, 50-70% of SDCs express epidermal growth factor receptor (EGFR; HER1) (17)(18)(19), and anti-EGFR-targeted therapies, such as cetuximab, are expected to be useful as novel SDC treatments.…”

Section: Introductionmentioning

confidence: 99%

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Kawahara

Hiraki

Yoshida

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes. Radical resection of the tumor and submandibular gland with neck dissection were performed. One month after radical surgery, computed tomography (CT) scans indicated metastasis in the lower lobe of the left lung. CT-guided transthoracic fine-needle aspiration biopsy revealed a single metastasis and lung metastasectomy was immediately performed. The tumor cells of the primary lesion and those of the lung metastasis were immunohistochemically positive for epidermal growth factor receptor. One month later, multiple right lung metastases appeared, and the patient was treated with cisplatin/5-fluorouracil (5-FU) chemotherapy plus cetuximab, achieving a complete radiographic response. However, multiple lung metastases developed during adjuvant weekly cetuximab monotherapy. Subsequently, treatment with S-1 and weekly cetuximab was initiated, and the multiple lung metastases have been maintained as stable disease for 5 months. To the best of our knowledge, this is the first report of cetuximab use for the treatment of salivary duct carcinoma. Although cisplatin/5-FU chemotherapy plus cetuximab was efficacious in treating the lung metastasis, cetuximab monotherapy was insufficient for controlling tumor growth.

show abstract

“…SDC is usually a high-grade malignant tumor, but low-grade SDC and intraductal SDC have also been reported ( 8 ). High-grade SDC is histopathologically characterized by proliferation of dysplastic cells containing large round to oval nuclei with conspicuous nucleoli and rich eosinophilic cytoplasm, occasionally accompanied by comedo necrosis, which resembles high-grade breast carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Salivary Duct Carcinoma with Late Distant Brain and Cutaneous Metastasis: A Case Report

et al. 2020

View full text Add to dashboard Cite

Salivary duct carcinoma (SDC) is a rare and highly aggressive salivary gland tumor with poor prognosis, rapid growth, distant metastasis, early regional metastasis, and a high rate of recurrence. The parotid gland is the most common site of involvement, and the lungs and the bones are the most common sites of distant metastasis of SDC. Herein, we present a case of SDC of the parotid gland in a 62-year-old male patient with an unusual metastasis to the skin of the primary site and brain 6 years after primary treatment, which comprised of total parotidectomy and radical neck dissection followed by radiotherapy. It is noteworthy that in few cases of SDC with infiltration, (and not in low-grade intraductal carcinoma of the salivary glands), routine treatment may not suffice, and long-term follow-up is highly recommended.

show abstract

Salivary duct carcinoma of the parotid gland: A case report and review of the literature

Cited by 8 publications

References 10 publications

Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland

Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Salivary Duct Carcinoma with Late Distant Brain and Cutaneous Metastasis: A Case Report

Contact Info

Product

Resources

About